The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications
Abstract
In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has received enthusiastic investigation, and significant progress has been made toward understanding its tumorigenic role and clinical significance. Among various thyroid tumors, this mutation occurs uniquely in papillary thyroid cancer (PTC), the most common endocrine malignancy, and some apparently PTC-derived anaplastic thyroid cancers. Many studies have found this mutation to be associated with those clinicopathological characteristics of PTC that are conventionally known to predict tumor progression and recurrence, including, for example, old patient age, extrathyroidal invasion, lymph node metastasis, and advanced tumor stages. Direct association of BRAF mutation with the clinical progression, recurrence, and treatment failure of PTC has also been demonstrated. The BRAF mutation has even been correlated with PTC recurrence in patients with conventionally low-risk clinicopathological factors. Some molecular mechanisms determining BRAF mutation-promoted progression and the aggressiveness of PTC have recently been uncovered. These include the down-regulation of major tumor suppressor genes and thyroid iodide-metabolizing genes and the up-regulation of cancer-promoting molecules, such as vascular endothelial growth factor, matrix metalloproteinases, nuclear transcription factor kappaB, and c-Met. Thus, BRAF mutation represents a novel indicator of the progression and aggressiveness of PTC. Significant advances have also occurred in the preclinical testing of new therapeutic strategies targeting the MAPK pathway aberrantly activated by BRAF mutation and other related mutations. New mitogen extracellular kinase (MEK) inhibitors developed recently are particularly promising therapeutic agents for thyroid cancer. With these advances, it has become clearer that BRAF mutation will likely have significant impact on the clinical management of PTC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Melillo, R. M., Castellone, M. D., Guarino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87345 · Cited by 306
RetractedMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,369
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
microRNAs as oncogenes and tumor suppressors
Zhang, B., Pan, X., Cobb, G. P., & Anderson, T. A. (2007) · Developmental Biology · doi:10.1016/j.ydbio.2006.08.028 · Cited by 2,749
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer
Mazzaferri, E. L., & Jhiang, S. M. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90321-2 · Cited by 2,635
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
PI3K/Akt signalling pathway and cancer
Vara, J. Á. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, M. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.007 · Cited by 2,443
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Sherman, S. I., & Tuttle, R. M. (2006) · Thyroid · doi:10.1089/thy.2006.16.109 · Cited by 2,016
Weisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A., Kang, G. H., Widschwendter, M., Weener, D., Buchanan, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1834 · Cited by 1,990
Matrix metalloproteinases and tumor metastasis
Deryugina, E. I., & Quigley, J. P. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-7886-9 · Cited by 1,960
Hundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,510
Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer
Mazzaferri, E. L. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.4.1447 · Cited by 1,396
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
Self-citationTargeting the mitogen-activated protein kinase cascade to treat cancer
Sebolt-Leopold, J. S., & Herrera, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1503 · Cited by 1,108
CpG island methylator phenotype in cancer
Issa, J.-P. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1507 · Cited by 1,098
Natural History, Treatment, and Course of Papillary Thyroid Carcinoma*
DEGROOT, L. J., KAPLAN, E. L., MCCORMICK, M., & STRAUS, F. H. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-2-414 · Cited by 1,049
Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030838 · Cited by 1,042
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0987 · Cited by 993
Self-citationBlockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 970
BRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
Self-citationGarnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799
Outcomes of Patients with Differentiated Thyroid Carcinoma Following Initial Therapy
Jonklaas, J., Sarlis, N. J., Litofsky, D., Ain, K. B., Bigos, S. T., Brierley, J. D., Cooper, D. S., Haugen, B. R., Ladenson, P. W., Magner, J., et al. (2006) · Thyroid · doi:10.1089/thy.2006.16.1229 · Cited by 695
Hoshino, R., Chatani, Y., Yamori, T., Tsuruo, T., Oka, H., Yoshida, O., Shimada, Y., Ari-i, S., Wada, H., Fujimoto, J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202367 · Cited by 691
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
Soares, P., Trovisco, V., Rocha, A. S., Lima, J., Castro, P., Preto, A., Máximo, V., Botelho, T., Seruca, R., & Sobrinho-Simões, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206706 · Cited by 679
Qi, J. H., Ebrahem, Q., Moore, N., Murphy, G., Claesson-Welsh, L., Bond, M., Baker, A., & Anand-Apte, B. (2003) · Nature Medicine · doi:10.1038/nm846 · Cited by 658
Rinehart, J., Adjei, A. A., LoRusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.185 · Cited by 645
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., Marais, R., Gibbens, I., Hackett, S., James, M., Schuchter, L. M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603291 · Cited by 644
Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers
Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., Ohtsuru, A., Saenko, V. A., Kanematsu, T., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030305 · Cited by 533
Adeniran, A. J., Zhu, Z., Gandhi, M., Steward, D. L., Fidler, J. P., Giordano, T. J., Biddinger, P. W., & Nikiforov, Y. E. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000176432.73455.1b · Cited by 495
The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer
Kebebew, E., Weng, J., Bauer, J., Ranvier, G., Clark, O. H., Duh, Q.-Y., Shibru, D., Bastian, B., & Griffin, A. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e318148563d · Cited by 480
BAY 43-9006 Inhibition of Oncogenic RET Mutants
Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G., Wilhelm, S. M., & Santoro, M. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj069 · Cited by 476
Adnane, L., Trail, P. A., Taylor, I., & Wilhelm, S. M. (2006) · Methods in Enzymology · doi:10.1016/s0076-6879(05)07047-3 · Cited by 463
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
Ciampi, R., Knauf, J. A., Kerler, R., Gandhi, M., Zhu, Z., Nikiforova, M. N., Rabes, H. M., Fagin, J. A., & Nikiforov, Y. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523237 · Cited by 461
Raf proteins and cancer: B-Raf is identified as a mutational target
Mercer, K. E., & Pritchard, C. A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00016-7 · Cited by 457
Targeting the c-Met Signaling Pathway in Cancer
Peruzzi, B., & Bottaro, D. P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0818 · Cited by 448
Hou, P., Liu, D., Shan, Y., Hu, S., Studeman, K., Condouris, S., Wang, Y., Trink, A., El-Naggar, A. K., Tallini, G., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1125 · Cited by 418
Self-citationTargeting the ERK signaling pathway in cancer therapy
Kohno, M., & Pouyssegur, J. (2006) · Annals of Medicine · doi:10.1080/07853890600551037 · Cited by 416
High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu, X., Quiros, R. M., Gattuso, P., Ain, K. B., & Prinz, R. A. (2003) · PubMed · Cited by 415
Knauf, J. A., Ma, X., Smith, E. P., Zhang, L., Mitsutake, N., Liao, X.-H., Refetoff, S., Nikiforov, Y. E., & Fagin, J. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0047 · Cited by 414
National Thyroid Cancer Treatment Cooperative Study Registr Group, Sherman, S. I., Brierley, J. D., Sperling, M., Ain, K. B., Bigos, S. T., Cooper, D. S., Haugen, B. R., Ho, M., Klein, I., et al. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980901)83:5<1012::aid-cncr28>3.0.co;2-9 · Cited by 402
LoRusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., Hanson, L., DeLuca, P., Bruzek, L., Piens, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.415 · Cited by 401
BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism
Durante, C., Puxeddu, E., Ferretti, E., Morisi, R., Moretti, S., Bruno, R., Barbi, F., Avenia, N., Scipioni, A., Verrienti, A., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2707 · Cited by 397
Lupi, C., Giannini, R., Ugolini, C., Proietti, A., Berti, P., Minuto, M., Materazzi, G., Elisei, R., Santoro, M., Miccoli, P., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1179 · Cited by 391
Leenhardt, L., Grosclaude, P., & Chérié-Challine, L. (2004) · Thyroid · doi:10.1089/thy.2004.14.1056 · Cited by 384
Giordano, T. J., Kuick, R., Thomas, D. G., Misek, D. E., Vinco, M., Sanders, D., Zhu, Z., Ciampi, R., Roh, M., Shedden, K., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208822 · Cited by 383
Riesco-Eizaguirre, G., Gutiérrez-Martínez, P., García-Cabezas, M. A., Nistal, M., & Santisteban, P. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01119 · Cited by 376
Zhu, Z., Gandhi, M., Nikiforova, M. N., Fischer, A. H., & Nikiforov, Y. E. (2003) · American Journal of Clinical Pathology · doi:10.1309/nd8d-9laj-trct-g6qd · Cited by 371
ras Mutations Are Associated With Aggressive Tumor Phenotypes and Poor Prognosis in Thyroid Cancer
Garcia-Rostan, G., Zhao, H., Camp, R. L., Pollan, M., Herrero, A., Pardo, J., Wu, R., Carcangiu, M. L., Costa, J., & Tallini, G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.130 · Cited by 368
BRAF mutations are associated with some histological types of papillary thyroid carcinoma
Trovisco, V., Vieira de Castro, I., Soares, P., Máximo, V., Silva, P., Magalhães, J., Abrosimov, A., Guiu, X. M., & Sobrinho‐Simões, M. (2004) · The Journal of Pathology · doi:10.1002/path.1511 · Cited by 363
Zhu, Z., Gandhi, M., Nikiforova, M. N., Fischer, A. H., & Nikiforov, Y. E. (2003) · American Journal of Clinical Pathology · doi:10.1309/nd8d9lajtrctg6qd · Cited by 355
Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer
García-Rostán, G., Costa, A. M., Pereira-Castro, I., Salvatore, G., Hernandez, R., Hermsem, M. J. A., Herrero, A., Fusco, A., Cameselle-Teijeiro, J., & Santoro, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4259 · Cited by 338
Specific Pattern of RAS Oncogene Mutations in Follicular Thyroid Tumors
Vasko, V., Ferrand, M., Di Cristofaro, J., Carayon, P., Henry, J. F., & de Micco, C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021186 · Cited by 310
BRAF mutations in papillary carcinomas of the thyroid
Fukushima, T., Suzuki, S., Mashiko, M., Ohtake, T., Endo, Y., Takebayashi, Y., Sekikawa, K., Hagiwara, K., & Takenoshita, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206739 · Cited by 297
Li, H., Myeroff, L., Smiraglia, D., Romero, M. F., Pretlow, T. P., Kasturi, L., Lutterbaugh, J., Rerko, R. M., Casey, G., Issa, J.-P., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1430846100 · Cited by 295
Lee, J., Lee, E., & Kim, Y. (2007) · Cancer · doi:10.1002/cncr.22754 · Cited by 291
Wilhelm, S., & Chien, D.-S. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023393026 · Cited by 289
New insight into BRAF mutations in cancer
Dhomen, N., & Marais, R. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.005 · Cited by 278
Frattini, M., Ferrario, C., Bressan, P., Balestra, D., De Cecco, L., Mondellini, P., Bongarzone, I., Collini, P., Gariboldi, M., Pilotti, S., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207980 · Cited by 266
BRAFV599EMutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas
Puxeddu, E., Moretti, S., Elisei, R., Romei, C., Pascucci, R., Martinelli, M., Marino, C., Avenia, N., Rossi, E. D., Fadda, G., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031425 · Cited by 260
CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)
ALLEN, L. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.012 · Cited by 257
Trovisco, V., Soares, P., Preto, A., de Castro, I. V., Lima, J., Castro, P., Máximo, V., Botelho, T., Moreira, S., Meireles, A. M., et al. (2005) · Virchows Archiv · doi:10.1007/s00428-005-1236-0 · Cited by 253
Control of the ERK MAP kinase cascade by Ras and Raf.
Marais, R., & Marshall, C. (1996) · PubMed · Cited by 246
Melillo, R. M., Castellone, M. D., Guarino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522758 · Cited by 242
RET/PTC Rearrangements and BRAF Mutations in Thyroid Tumorigenesis
Ciampi, R., & Nikiforov, Y. E. (2007) · Endocrinology · doi:10.1210/en.2006-0921 · Cited by 241
Kim, T. Y., Kim, W. B., Rhee, Y. S., Song, J. Y., Kim, J. M., Gong, G., Lee, S., Kim, S. Y., Kim, S. C., Hong, S. J., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02605.x · Cited by 238
Fugazzola, L., Puxeddu, E., Avenia, N., Romei, C., Cirello, V, Cavaliere, A., Faviana, P., Mannavola, D., Moretti, S., Rossi, S., et al. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01086 · Cited by 237
Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population
Kim, K. H., Kang, D. W., Kim, S. H., Seong, I. O., & Kang, D. Y. (2004) · Yonsei Medical Journal · doi:10.3349/ymj.2004.45.5.818 · Cited by 229
Mitsutake, N., Knauf, J. A., Mitsutake, S., Mesa, C., Zhang, L., & Fagin, J. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3314 · Cited by 228
Thyroid-hormone therapy and thyroid cancer: a reassessment
Biondi, B., Filetti, S., & Schlumberger, M. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0020 · Cited by 224
Quiros, R. M., Ding, H. G., Gattuso, P., Prinz, R. A., & Xu, X. (2005) · Cancer · doi:10.1002/cncr.21073 · Cited by 223
Kim, T. Y., Kim, W. B., Song, J. Y., Rhee, Y. S., Gong, G., Cho, Y. M., Kim, S. Y., Kim, S. C., Hong, S. J., & Shong, Y. K. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02389.x · Cited by 221
Fahey, T. J. (2006) · Yearbook of Surgery · doi:10.1016/s0090-3671(08)70420-8 · Cited by 218
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery
THOMPSON, N., & LYONS, J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.007 · Cited by 214
Venkataraman, G. M., Yatin, M., Marcinek, R., & Ain, K. B. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5815 · Cited by 202
Liu, D., Hu, S., Hou, P., Jiang, D., Condouris, S., & Xing, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1753 · Cited by 202
Self-citationJarząb, B., Handkiewicz-Junak, D., & Włoch, J. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00880 · Cited by 198
Hu, S., Liu, D., Tufano, R. P., Carson, K. A., Rosenbaum, E., Cohen, Y., Holt, E. H., Kiseljak‐Vassiliades, K., Rhoden, K. J., Tolaney, S., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22110 · Cited by 197
Self-citationUncommon Mutation, but Common Amplifications, of the PIK3CA Gene in Thyroid Tumors
Wu, G., Mambo, E., Guo, Z., Hu, S., Huang, X., Gollin, S. M., Trink, B., Ladenson, P. W., Sidransky, D., & Xing, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2281 · Cited by 191
Self-citationRET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture
Santoro, M., Melillo, R. M., & Fusco, A. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02289 · Cited by 190
BRAF mutations in an Italian cohort of thyroid cancers
Fugazzola, L., Mannavola, D., Cirello, V., Vannucchi, G., Muzza, M., Vicentini, L., & Beck‐Peccoz, P. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02089.x · Cited by 184
Knauf, J. A., Kuroda, H., Basu, S., & Fagin, J. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206602 · Cited by 181
Begum, S., Rosenbaum, E., Henrique, R., Cohen, Y., Sidransky, D., & Westra, W. H. (2004) · Modern Pathology · doi:10.1038/modpathol.3800198 · Cited by 175
Gene Methylation in Thyroid Tumorigenesis
Xing, M. (2007) · Endocrinology · doi:10.1210/en.2006-0927 · Cited by 174
Self-citationClinical experience of MEK inhibitors in cancer therapy
Wang, D., Boerner, S. A., Winkler, J. D., & LoRusso, P. M. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.11.009 · Cited by 172
BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma
Salvatore, G., De Falco, V., Salerno, P., Nappi, T. C., Pepe, S., Troncone, G., Carlomagno, F., Melillo, R. M., Wilhelm, S. M., & Santoro, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2378 · Cited by 172
Chung, K., Yang, S. K., Lee, G. K., Kim, E. Y., Kwon, S., Lee, S. H., Park, D. J., Lee, H. S., Cho, B. Y., Lee, E. S., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02646.x · Cited by 171
Fagin, J. A. (2004) · Journal of Endocrinology · doi:10.1677/joe.1.05895 · Cited by 171
Jo, Y. S., Li, S., Song, J. H., Kwon, K. H., Lee, J. C., Rha, S. Y., Lee, H. J., Sul, J. Y., Kweon, G. R., Ro, H.-K., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2836 · Cited by 160
Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma
Flaherty, K. T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2505 · Cited by 159
Pendrin Is an Iodide-Specific Apical Porter Responsible for Iodide Efflux from Thyroid Cells
Yoshida, A. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.7.3356 · Cited by 158
Xing, M., Usadel, H., Cohen, Y., Tokumaru, Y., Guo, Z., Westra, W. B., Tong, B. C., Tallini, G., Udelsman, R., Califano, J. A., et al. (2003) · PubMed · Cited by 151
Self-citationQuantitative Assessment of Promoter Methylation Profiles in Thyroid Neoplasms
Hoque, M. O., Rosenbaum, E., Westra, W. H., Xing, M., Ladenson, P. W., Zeiger, M. A., Sidransky, D., & Umbricht, C. B. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0313 · Cited by 149
Self-citationMitogen-Activated Protein Kinases in Cell-Cycle Control
MacCorkle, R. A., & Tan, T. (2005) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:43:3:451 · Cited by 149
Regulatory Mechanisms and Function of ERK MAP Kinases
Torii, S., Nakayama, K., Yamamoto, T., & Nishida, E. (2004) · The Journal of Biochemistry · doi:10.1093/jb/mvh159 · Cited by 147
Anand‐Apte, B., Bao, L., Smith, R. C., Zetter, B. R., Iwata, K., Olsen, B. R., & Apte, S. (1996) · Biochemistry and Cell Biology · doi:10.1139/o96-090 · Cited by 147
Xing, M., Cohen, Y., Mambo, E., Tallini, G., Udelsman, R., Ladenson, P. W., & Sidransky, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3242 · Cited by 143
Self-citationGhossein, R. A., Leboeuf, R., Patel, K. N., Rivera, M., Katabi, N., Carlson, D. L., Tallini, G., Shaha, A. R., Singh, B., & Tuttle, R. M. (2007) · Thyroid · doi:10.1089/thy.2007.0061 · Cited by 141
Ouyang, B., Knauf, J. A., Smith, E. P., Zhang, L., Ramsey, T., Yusuff, N., Batt, D. B., & Fagin, J. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1729 · Cited by 138
Mesa, C. O., Mirza, M., Mitsutake, N., Sartor, M. A., Medvedovic, M., Tomlinson, C. R., Knauf, J. A., Weber, G. F., & Fagin, J. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0739 · Cited by 136
Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade.
Collisson, E. A., De, A., Suzuki, H., Gambhir, S. S., & Kolodney, M. S. (2003) · PubMed · Cited by 129
Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake
Mian, C., Barollo, S., Pennelli, G., Pavan, N., Rugge, M., Pelizzo, M. R., Mazzarotto, R., Casara, D., Nacamulli, D., Mantero, F., et al. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03008.x · Cited by 129
Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma
Michels, J. J., Jacques, M., Henry-Amar, M., & Bardet, S. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.08.001 · Cited by 128
Liu, D., Liu, Z., Condouris, S., & Xing, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1613 · Cited by 126
Self-citationHypermethylation of the Retinoic Acid Receptor -β 2 Gene in Head and Neck Carcinogenesis
Youssef, E. M., Lotan, D., Issa, J. J., Wakasa, K., Fan, Y.-H., Mao, L., Hassan, K. A., Feng, L., Lee, J. J., Lippman, S. M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0989-3 · Cited by 126
Paroder, V., Spencer, S. R., Paroder, M., Arango, D., Schwartz, S., Mariadason, J., Augenlicht, L., Eskandari, S., & Carrasco, N. (2006) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0602365103 · Cited by 123
Pohl, G., Ho, C., Kurman, R. J., Bristow, R. E., Wang, T., & Shih, I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3625 · Cited by 123
Vasko, V. V., Hu, S., Wu, G., Xing, J. C., Ларін, О. С., Savchenko, V., Trink, B., & Xing, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2353 · Cited by 121
Self-citationVenkataraman, G. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.7.2449 · Cited by 119
Mitsutake, N., Miyagishi, M., Mitsutake, S., Akeno, N., Mesa, C. O., Knauf, J. A., Zhang, L., Taira, K., & Fagin, J. A. (2005) · Endocrinology · doi:10.1210/en.2005-0280 · Cited by 118
BRAFV600EPromotes Invasiveness of Thyroid Cancer Cells through Nuclear Factor κB Activation
Palona, I., Namba, H., Mitsutake, N., Starenki, D., Podtcheko, A., Sedliarou, I., Ohtsuru, A., Saenko, V., Nagayama, Y., Umezawa, K., et al. (2006) · Endocrinology · doi:10.1210/en.2006-0400 · Cited by 112
Ball, D. W., Jin, N. Y., Rosen, D. M., Dackiw, A. P. B., Sidransky, D., Xing, M., & Nelkin, B. D. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1184 · Cited by 109
Self-citationGiannini, R., Ugolini, C., Lupi, C., Proietti, A., Elisei, R., Salvatore, G., Berti, P., Materazzi, G., Miccoli, P., Santoro, M., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0594 · Cited by 108
Porra, V., Ferraro‐Peyret, C., Durand, C., Selmi‐Ruby, S., Giroud, H., Berger-Dutrieux, N., Decaussin‐Petrucci, M., Peix, J., Bournaud, C., Orgiazzi, J., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1394 · Cited by 108
Cancer Targets in the Ras PathwayPreprint
Rodriguez‐Viciana, P., Tetsu, O., ODA, K., Okada, J., Rauen, K. A., & McCormick, F. P. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.044 · Cited by 107
Targeting BRAF in thyroid cancer
Espinosa, A. V., Porchia, L. M., & Ringel, M. D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603520 · Cited by 104
Pro-angiogenic cytokines and their role in tumor angiogenesis
Neufeld, G., & Kessler, O. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9011-5 · Cited by 103
Powell, N. G., Jeremiah, S., Morishita, M., Dudley, E., Bethel, J., Ti, B., Tronko, M. D., & Thomas, G. A. (2005) · The Journal of Pathology · doi:10.1002/path.1736 · Cited by 102
Cristofaro, J. D., Marcy, M., Vasko, V. V., Sebag, F. A., Fakhry, N., Wynford‐Thomas, D., & Micco, C. D. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.01.030 · Cited by 102
Sapio, M. R., Posca, D., Troncone, G., Pettinato, G., Palombini, L., Rossi, G., Fenzi, G., & Vitale, M. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02072 · Cited by 102
Schagdarsurengin, U., Gimm, O., Dralle, H., Hoang‐Vu, C., & Dammann, R. (2006) · Thyroid · doi:10.1089/thy.2006.16.633 · Cited by 101
Preventable reoperations for persistent and recurrent papillary thyroid carcinoma
Kouvaraki, M. A., Lee, J. E., Shapiro, S. E., Sherman, S. I., & Evans, D. B. (2004) · Surgery · doi:10.1016/j.surg.2004.06.045 · Cited by 98
Pizzolanti, G., Russo, L., Richiusa, P., Bronte, V., Nuara, R. B., Rodolico, V., Amato, M. C., Smeraldi, L., Sisto, P. S., Nucera, M., et al. (2007) · Thyroid · doi:10.1089/thy.2007.0008 · Cited by 95
Characterization of the 5'-flanking region of the rat thyrotropin receptor gene
Ikuyama, S., Niller, H. H., Shimura, H., Akamizu, T., & Kohn, L. D. (1992) · Molecular Endocrinology · doi:10.1210/mend.6.5.1318504 · Cited by 92
Hou, P., Liu, D., & Xing, M. (2007) · Cell Cycle · doi:10.4161/cc.6.3.3818 · Cited by 87
Self-citationWang, J., Knauf, J. A., Basu, S., Puxeddu, E., Kuroda, H., Santoro, M., Fusco, A., & Fagin, J. A. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0041 · Cited by 83
Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer.
Kim, D., Cheng, G. Z., Lindsley, C. W., Yang, H., & Cheng, J. Q. (2005) · PubMed · Cited by 81
B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas
Trovisco, V., Soares, P., & Sobrinho-Simões, M. A. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.03.013 · Cited by 81
The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma
Sedliarou, I., Saenko, V., Lantsov, D., Rogounovitch, T., Namba, H., Abrosimov, A., Lushnikov, E. F., Kumagai, A., Nakashima, M., Meirmanov, S. K., et al. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.6.1729 · Cited by 80
Lymphatic Mapping Establishes the Role of BRAF Gene Mutation in Papillary Thyroid Carcinoma
Kim, J., Giuliano, A. E., Turner, R. R., Gaffney, R., Umetani, N., Kitago, M., Elashoff, D. A., & Hoon, D. S. �. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000224751.80858.13 · Cited by 79
Carta, C., Moretti, S., Passeri, L., Barbi, F., Avenia, N., Cavaliere, A., Monacelli, M., Macchiarulo, A., Santeusanio, F., Tartaglia, M., et al. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02401.x · Cited by 79
Rodolico, V., Cabibi, D., Pizzolanti, G., Richiusa, P., Gebbia, N., Martorana, A., Russo, A. D., Amato, M. C., Galluzzo, A., & Giordano, C. S. D. S. (2007) · Cancer · doi:10.1002/cncr.22912 · Cited by 79
Arturi, F., Russo, D., Bidart, J., Scarpelli, D. G., Schlumberger, M. J., & Filetti, S. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1450129 · Cited by 77
Hahn, O. M., & Stadler, W. M. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000245316.82391.52 · Cited by 77
Vitagliano, D., Portella, G., Troncone, G., Francione, A., Rossi, C., Bruno, A., Giorgini, A., Coluzzi, S., Nappi, T. C., Rothstein, J. L., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209527 · Cited by 76
Darnton, S. J., Hardie, L. J., Muc, R. S., Wild, C. P., & Casson, A. G. (2005) · International Journal of Cancer · doi:10.1002/ijc.20830 · Cited by 71
Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis
Kim, K., Suh, K., Kang, D., & Kang, D. (2005) · Pathology International · doi:10.1111/j.1440-1827.2005.01866.x · Cited by 71
Hong, C., Maunakea, A. K., Jun, P., Bollen, A. W., Hodgson, J., Goldenberg, D., Weiss, W. A., & Costello, J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0048 · Cited by 71
Progress Towards Therapeutic Small Molecule MEK Inhibitors for Use in Cancer Therapy
Wallace, E. M., Lyssikatos, J. P., Yeh, T. C., Winkler, J. D., & Koch, K. M. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026053507723 · Cited by 70
Cahill, S., Smyth, P. C., Denning, K. M., Flavin, R., Li, J., Potratz, A., Guenther, S. M., Henfrey, R. D., O’Leary, J. J., & Sheils, O. M. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-21 · Cited by 69
Thyroid Cancer Clinical Practice Guidelines in Oncology
Sherman, S. I., Angelos, P., Ball, D. W., Beenken, S. W., Byrd, D. R., Clark, O. H., Daniels, G. H., Dilawari, R. A., Ehya, H., Farrar, W. B., et al. (2005) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2005.0021 · Cited by 69
Total thyroidectomy for differentiated thyroid cancer
Sosa, J. A., & Udelsman, R. (2006) · Journal of Surgical Oncology · doi:10.1002/jso.20695 · Cited by 68
Liu, D., Liu, Z., JIANG, D., Dackiw, A. P. B., & Xing, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0097 · Cited by 67
Self-citationHypermethylation of the Pendred syndrome gene SLC26A4 is an early event in thyroid tumorigenesis.
Xing, M., Tokumaru, Y., Wu, G., Westra, W. B., Ladenson, P. W., & Sidransky, D. (2003) · PubMed · Cited by 65
Self-citationGenetics of papillary thyroid cancer initiation: implications for therapy.
Fagin, J. A. (2005) · PubMed · Cited by 61
BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas
Lee, J. H., Lee, E. S., Kim, Y., Won, N. H., & Chae, Y. (2006) · Pathology · doi:10.1080/00313020600696264 · Cited by 60
BRAFV600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas
Takano, T., Ito, Y., Hirokawa, M., Yoshida, H., & Miyauchi, A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603764 · Cited by 60
Moretti, S., Macchiarulo, A., Falco, V. D., Avenia, N., Barbi, F., Carta, C., Cavaliere, A., Melillo, R. M., Passeri, L., Santeusanio, F., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209448 · Cited by 58
Cristofaro, J. D., Silvy, M., Lanteaume, A., Marcy, M., Carayon, P., & Micco, C. D. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01164 · Cited by 58
Yoon, H., He, H., Nagy, R. S., Davuluri, R. V., Suster, S. M., Schoenberg, D. R., Pellegata, N. S., & de la Chapelle, A. (2007) · International Journal of Cancer · doi:10.1002/ijc.22701 · Cited by 57
Targeting BRAFV600E in thyroid carcinoma: therapeutic implications
Mitsiades, C. S., Negri, J. M., McMullan, C. J., McMillin, D. W., Sozopoulos, E., Fanourakis, G., Voutsinas, G. E., Tseleni‐Balafouta, S., Poulaki, V., Batt, D. B., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0449 · Cited by 57
Iodide handling by the thyroid epithelial cell
Nilsson, M. (2001) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2001-11014 · Cited by 42
The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer
Xing, M. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02332.x · Cited by 39
Self-citationYokomori, N., Tawata, M., Saito, T., Shimura, H., & Onaya, T. (1998) · Molecular Endocrinology · doi:10.1210/me.12.8.1241 · Cited by 38
An Overview of the Management of Thyroid Cancer
Mazzaferri, E. L. (2006) · Springer eBooks · doi:10.1007/1-84628-013-3_1 · Cited by 27
Henderson, Y. C., Fredrick, M. J., & Clayman, G. L. (2007) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.133.8.810 · Cited by 19
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
Self-citationTargeting the MAPK–RAS–RAF signaling pathway in cancer therapy
Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645805 · Cited by 1,027
Molecular genetics and diagnosis of thyroid cancer
Nikiforov, Y. E., & Nikiforova, M. N. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.142 · Cited by 1,011
Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer
Xing, M., Alzahrani, A. S., Carson, K. A., Viola, D., Elisei, R., Bendlova, B., Yip, L., Mian, C., Vianello, F., Tuttle, R. M., et al. (2013) · JAMA · doi:10.1001/jama.2013.3190 · Cited by 940
Self-citation
Metadata
- Authors
- Xing, M.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2007-10-16
- Volume
- 28
- Issue
- 7
- Pages
- 742-762
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2101888941
- Cited by
- 983
- References
- 160
- FWCI
- 31.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.